Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733971 | 0.83 | GDA (0.34) | GDAACHEXDH | |
| SCHEMBL1919722 | 0.61 | — | — | |
| SCHEMBL535022 | 0.61 | QTRT1 (0.42) | XDH | |
| SCHEMBL14793670 | 0.61 | DPYD (0.31) | GDA | |
| SCHEMBL14793521 | 0.61 | TYMP (0.35) | GDA | |
| SCHEMBL13702507 | 0.60 | ALDH1A1 (0.36) | GDAACHEXDH | |
| SCHEMBL142922 | 0.57 | QTRT1 (0.42) | XDH | |
| SCHEMBL10766157 | 0.57 | PNP (0.38) | — | |
| SCHEMBL8259690 | 0.56 | ALDH1A1 (0.38) | GDA | |
| SCHEMBL9571553 | 0.55 | MAPT (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 494 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061450-B1 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MEDICAL COLLEGE WISCONSIN INC (US) | 2017-04-19 | — | — | EP | claimed |
| EP-1291343-B1 | HYDROXYFORMAMIDINE DERIVATIVES AND MEDICINES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-12-06 | — | — | EP | claimed |
| US-7078400-B2 | 20-HETE synthase inhibitor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-18 | — | — | US | claimed |
| EP-1226819-B1 | INHIBITOR FOR 20-HETE-YIELDING ENZYME | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-01-18 | — | — | EP | claimed |
| US-6864254-B1 | Inhibitor for 20-hete-yielding enzyme | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-03-08 | — | — | US | claimed |
| US-20040110830-A1 | 20-HETE synthase inhibitor | TAISHO PHARMACEUTICAL CO., LTD. | 2004-06-10 | — | — | US | claimed |
| EP-1409450-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 2004-04-21 | — | — | EP | claimed |
| US-6670382-B2 | For inhibiting a synthase of 20-hydroxyeicosatetraenoic acid biosynthesized from arachidonic acid involved in constriction or dilation of microvessels in the kidneys and the cerebral blood vessels, or participates in cell proliferation | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-30 | — | — | US | claimed |
| US-20030186979-A1 | Hydroxyformamidine derivatives and medicines containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | US | claimed |
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | claimed |
| EP-1291343-A1 | HYDROXYFORMAMIDINE DERIVATIVES AND MEDICINES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-03-12 | — | — | EP | claimed |
| WO-2003006423-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| EP-1226819-A1 | INHIBITOR FOR 20-HETE-YIELDING ENZYME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2002-07-31 | — | — | EP | claimed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | claimed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | claimed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | claimed |
| EP-0620813-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-10-26 | — | — | EP | claimed |
| WO-1993014069-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-07-22 | — | — | WO | claimed |
| EP-4398254-A2 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | Memorial Sloan Kettering Cancer Center (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12023371-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11981703-B2 | Polynucleotide constructs | SIRIUS THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240131193-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-25 | — | — | US | disclosed |
| US-20240123035-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-18 | — | — | US | disclosed |
| EP-4351662-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| EP-2991655-B1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794585-A | Radioimmunoconjugates and checkpoint inhibitor combination therapies | 融合制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3737673-B1 | PROCESS FOR PREPARING HALICHONDRIN MACROLIDES AND ANALOGS THEREOF BY A PRINS REACTION, AND INTERMEDIATES OF THIS PROCESS | EISAI R&D MAN CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| CN-117603148-A | Pharmacokinetic enhancement of difunctional chelates and uses thereof | 探针技术开发及商业化中心 | 2024-02-27 | — | — | CN | disclosed |
| US-20240042000-A1 | CARBOHYDRATE STRUCTURES AND USES THEREOF | 6452728 CANADA CORP (CA) | 2024-02-08 | — | — | US | disclosed |
| CN-117482261-A | Combination therapy of radioimmunoconjugates and checkpoint inhibitors | 融合制药公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4289950-A2 | MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF | Revolution Medicines, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117120086-A | Compositions and methods for cancer diagnosis | AOA DX公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117024469-A | Macrocyclization reactions useful for the synthesis of halichondrin macrolides, intermediates and other fragments | 卫材R&D管理有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-111263747-B | Pharmacokinetic enhancement of difunctional chelates and uses thereof | 探针技术开发及商业化中心 | 2023-10-27 | — | — | CN | disclosed |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11793895-B2 | Residualizing linkers and uses thereof | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION | 2023-10-24 | — | — | US | disclosed |
| US-11786586-B2 | Carbohydrate structures and uses thereof | AOA DX (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230323344-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | ARES CAPITAL CORPORATION, AS AGENT | 2023-10-12 | — | — | US | disclosed |
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| EP-4242304-A2 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | Warp Drive Bio, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230270895-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2023-08-31 | — | — | US | disclosed |
| CN-112250692-B | Macrocyclization reactions useful for the synthesis of halichondrin macrolides, intermediates and other fragments | 卫材R&D管理有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4225365-A1 | COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS | AOA Dx (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230242567-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SIRIUS THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11708396-B2 | Signal-sensor polynucleotides for the alteration of cellular phenotypes | MODERNATX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230227826-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| EP-3247378-B1 | MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF | WARP DRIVE BIO INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230151022-A1 | PRINS REACTION AND COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ANALOGS THEREOF | EISAI R&D MANAGEMENT CO, LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4159741-A1 | METHOD FOR PRODUCING A CHIMERIC POLYNUCLEOTIDE ENCODING A POLYPEPTIDE HAVING A TRIAZOLE-CONTAINING INTERNUCLEOTIDE LINKAGE | ModernaTX, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-11603399-B2 | Long-lived polynucleotide molecules | MODERNATX, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-4144378-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | ModernaTX, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11597744-B2 | Chiral phosphoramidite auxiliaries and methods of their use | SIRIUS THERAPEUTICS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230052140-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2023-02-16 | — | — | US | disclosed |
| US-11564998-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20230013773-A1 | SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-19 | — | — | US | disclosed |
| US-11542269-B2 | Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-01-03 | — | — | US | disclosed |
| WO-2022261467-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2022-12-15 | — | — | WO | disclosed |
| US-20220395562-A1 | TERMINALLY MODIFIED RNA | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-15 | — | — | US | disclosed |
| EP-4101930-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | ModernaTX, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220275362-A1 | METHODS FOR TAGGING AND ENCODING OF PRE-EXISTING COMPOUND LIBRARIES | X-CHEM, INC. (US) | 2022-09-01 | — | — | US | disclosed |
| CN-114929282-A | Asialoglycoprotein receptor mediated delivery of therapeutically active conjugates | 阿克丘勒斯治疗公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114805322-A | Prins reactions and intermediates useful for the synthesis of halichondrin macrolides and analogs thereof | 卫材R&D管理有限公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-4025252-A1 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4023249-A1 | NUCLEIC ACID VACCINES | ModernaTX, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220193223-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| EP-4015005-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-109641917-B | Prins reactions and intermediates useful for the synthesis of halichondrin macrolides and analogs thereof | 卫材R&D管理有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20220144849-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-05-12 | — | — | US | disclosed |
| US-20220143202-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WARP DRIVE BIO, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220088231-A1 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | OXFORD FINANCE LLC | 2022-03-24 | — | — | US | disclosed |
| EP-3169693-B1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX INC (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114144522-A | Methods for labeling and encoding pre-existing compound libraries | X-化学有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20220054664-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2022-02-24 | — | — | US | disclosed |
| EP-2922554-B1 | TERMINALLY MODIFIED RNA | MODERNATX INC (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210405060-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | Revolution Medicines, Inc. | 2021-12-30 | — | — | US | disclosed |
| WO-2021257916-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021257917-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-3134131-B1 | NUCLEIC ACID VACCINES | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11191854-B2 | Pharmacokinetic enhancements of bifunctional chelates and uses thereof | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2021-12-07 | — | — | US | disclosed |
| EP-3682905-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-113727999-A | Methods and compositions for treating cancer | 奥默罗斯公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3350333-B1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNATX INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| US-11136335-B2 | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-10-05 | — | — | US | disclosed |
| CN-113474014-A | Combination therapy of radioimmunoconjugates with inhibitors of DNA damage and repair | 融合制药公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210299278-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210290789-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2021-09-23 | — | — | US | disclosed |
| US-20210290788-A1 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2021-09-23 | — | — | US | disclosed |
| US-20210285955-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | WARP DRIVE BIO, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11117923-B2 | Immune modulatory compositions | RAJAPPAN KUMAR (US) | 2021-09-14 | — | — | US | disclosed |
| CN-113164632-A | Combination therapy of radioimmunoconjugates with checkpoint inhibitors | 融合制药公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210220467-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-11059830-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-11014956-B2 | Compositions and methods for altering second messenger signaling | Memorial Sloan Kettering Cancer Center; The Rockefeller (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210115101-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2021-04-22 | — | — | US | disclosed |
| US-10981929-B2 | — | — | 2021-04-20 | — | — | US | disclosed |
| US-20210077634-A1 | IN VIVO PRODUCTION OF PROTEINS | MODERNATX INC (US) | 2021-03-18 | — | — | US | disclosed |
| US-10948495-B2 | Methods and reagents for analyzing protein-protein interfaces | Revolution Medicines, Inc. (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2021046260-A1 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | ARCTURUS THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20210060168-A1 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | ARCTURUS THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210061843-A1 | MULTIMERIC POLYNUCLEOTIDES AND USES THEREOF | MODERNATX, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210060190-A1 | RESIDUALIZING LINKERS AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2021-03-04 | — | — | US | disclosed |
| CN-112390871-A | In vivo production of proteins | 现代泰克斯公司 | 2021-02-23 | — | — | CN | disclosed |
| US-10925935-B2 | Terminally Modified RNA | MODERNATX, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| CN-112386604-A | Modulators of cGAS | 纪念斯隆-凯特琳癌症中心 | 2021-02-23 | — | — | CN | disclosed |
| US-10913749-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-02-09 | — | — | US | disclosed |
| EP-3757109-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Warp Drive Bio, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| US-20200354423-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MODERNA THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200347074-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2020-11-05 | — | — | US | disclosed |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | OMEROS CORPORATOIN | 2020-11-05 | — | — | US | disclosed |
| CN-111868044-A | Prins reaction and compounds useful for the synthesis of halichondrin macrolides and analogs thereof | 卫材R&D管理有限公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3091970-B1 | LXR AGONISTS AND USES THEREOF | RGENIX INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331928-A1 | PRINS REACTION AND COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ANALOGS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-10-22 | — | — | US | disclosed |
| EP-3292130-B1 | MACROCYCLIZATION REACTIONS AND INTERMEDIATES AND OTHER FRAGMENTS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES | EISAI R&D MAN CO LTD (JP) | 2020-09-30 | — | — | EP | disclosed |
| US-10772975-B2 | Modified Polynucleotides for the production of biologics and proteins associated with human disease | MODERNATX, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200276190-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2020-09-03 | — | — | US | disclosed |
| US-10758636-B2 | Residualizing linkers and uses thereof | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2020-09-01 | — | — | US | disclosed |
| US-20200247861-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | MODERNA THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
| EP-3682905-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10709779-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10703789-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200199102-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
| EP-2971010-B1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX INC (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-111263747-A | Bifunctional chelate pharmacokinetics enhancement and uses thereof | 融合制药公司 | 2020-06-09 | — | — | CN | disclosed |
| US-10669296-B2 | LXR agonists and uses thereof | RGENIX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200164038-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155706-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2020-05-21 | — | — | US | disclosed |
| US-20200140476-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SIRIUS THERAPEUTICS, INC. | 2020-05-07 | — | — | US | disclosed |
| CN-110891614-A | IGF-1R monoclonal antibody and application thereof | 融合制药公司 | 2020-03-17 | — | — | CN | disclosed |
| US-10583203-B2 | In vivo production of proteins | MODERNATX, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| EP-3492109-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-10577403-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20200062799-A1 | IMMUNE MODULATORY COMPOSITIONS | RAJAPPAN KUMAR (US) | 2020-02-27 | — | — | US | disclosed |
| CN-110831632-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110785428-A | Methods and reagents for analyzing protein-protein interfaces | 锐新医药公司 | 2020-02-11 | — | — | CN | disclosed |
| US-10501512-B2 | Modified polynucleotides | MODERNATX, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-20190343941-A1 | CARBOHYDRATE STRUCTURES AND USES THEREOF | AOA DX | 2019-11-14 | — | — | US | disclosed |
| US-10463751-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10466249-B2 | Methods and reagents for analyzing protein-protein interfaces | Revolution Medicines, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190330257-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-10-31 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315824-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MODERNATX, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190314527-A1 | IN VIVO PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190308992-A1 | MACROCYCLIZATION REACTIONS AND INTERMEDIATES AND OTHER FRAGMENTS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-10 | — | — | US | disclosed |
| US-20190290742-A1 | TERMINALLY MODIFIED RNA | MODERNATX, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-10407683-B2 | Circular polynucleotides | MODERNATX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3169335-B1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-2931319-B1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10385106-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385091-B2 | Compositions and methods for altering second messenger signaling | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385088-B2 | Polynucleotide molecules and uses thereof | MODERNATX, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190240351-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS | MODERNATX, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-3520821-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | Moderna Therapeutics, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3520820-A1 | IN VIVO PRODUCTION OF PROTEINS | Moderna Therapeutics, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190202855-A1 | POLYNUCLEOTIDE CONSTRUCTS | SIRIUS THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| EP-3505176-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | Moderna Therapeutics, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190194655-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | BRADSHAW CURT W (US) | 2019-06-27 | — | — | US | disclosed |
| EP-3501550-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | Moderna Therapeutics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190185529-A1 | SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES | MODERNA THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| EP-3492109-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10308661-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-04 | — | — | US | disclosed |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190161495-A1 | PRINS REACTION AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ANALOGS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
| US-20190142971-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190144503-A1 | METHODS FOR THE IDENTIFICATION OF BIFUNCTIONAL COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2019-05-16 | — | — | US | disclosed |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | MODERNATX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10258698-B2 | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions | MODERNATX, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| EP-3068443-B1 | RESIDUALIZING LINKERS AND USES THEREOF | CENTRE FOR PROBE DEV AND COMMERCIALIZATION (CA) | 2019-04-10 | — | — | EP | disclosed |
| US-20190083662-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | OXFORD FINANCE LLC | 2019-03-21 | — | — | US | disclosed |
| US-20190078087-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | ARES CAPITAL CORPORATION, AS AGENT | 2019-03-14 | — | — | US | disclosed |
| US-20190055277-A1 | Immune Modulatory Compositions | RAJAPPAN KUMAR (US) | 2019-02-21 | — | — | US | disclosed |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190030194-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2019-01-31 | — | — | US | disclosed |
| EP-3434774-A1 | SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES | ModernaTX, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20190015501-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190008948-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-10 | — | — | US | disclosed |
| US-20190000959-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180360995-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES | MODERNA THERAPEUTICS, INC. | 2018-12-20 | — | — | US | disclosed |
| EP-2763701-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10155029-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2018-12-18 | — | — | US | disclosed |
| WO-2018222975-A1 | METHODS FOR THE TREATMENT OF CANCER | RGENIX, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| EP-2833922-B1 | IN VIVO PRODUCTION OF PROTEINS | MODERNA THERAPEUTICS INC (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-3402477-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | The Rockefeller University (US) | 2018-11-21 | — | — | EP | disclosed |
| US-10131686-B2 | Compositions and methods for altering second messenger signaling | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180318434-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2018-11-08 | — | — | US | disclosed |
| US-20180311381-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-01 | — | — | US | disclosed |
| US-20180303864-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-10-25 | — | — | US | disclosed |
| EP-3386517-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | Solstice Biologics, Ltd. (IE) | 2018-10-17 | — | — | EP | disclosed |
| US-20180291335-A1 | MODIFIED POLYNUCLEOTIDES FOR ALTERING CELL PHENOTYPE | MODERNA THERAPEUTICS, INC. | 2018-10-11 | — | — | US | disclosed |
| US-10093741-B1 | IGF-1R monoclonal antibodies and uses thereof | Fusion Pharmaceuticals Inc. (CA) | 2018-10-09 | — | — | US | disclosed |
| US-20180273544-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2018-09-27 | — | — | US | disclosed |
| US-20180259535-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2018-09-13 | — | — | US | disclosed |
| US-20180256750-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNA THERAPEUTICS, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180252726-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2018-09-06 | — | — | US | disclosed |
| EP-3366685-A1 | TRYPTOLINE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-Chem, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-10039839-B2 | Compounds that participate in cooperative binding and uses thereof | WARP DRIVE BIO, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10022435-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-9989535-B2 | Methods and reagents for analyzing protein-protein interfaces | WARP DRIVE BIO, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127454-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-10 | — | — | US | disclosed |
| US-20180118755-A1 | MACROCYCLIZATION REACTIONS AND INTERMEDIATES AND OTHER FRAGMENTS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180118777-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER | 2018-05-03 | — | — | US | disclosed |
| US-9950001-B2 | Polynucleotides having bioreversible groups | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085391-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | MODERNA THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086816-A1 | LONG-LIVED POLYNUCLEOTIDE MOLECULES | ARES CAPITAL CORPORATION, AS AGENT | 2018-03-29 | — | — | US | disclosed |
| EP-2802328-B1 | TRYPTOLINE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-CHEM INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9878056-B2 | Modified polynucleotides for the production of cosmetic proteins and peptides | MODERNATX, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9872900-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20180000910-A1 | TERMINALLY MODIFIED RNA | ARES CAPITAL CORPORATION, AS AGENT | 2018-01-04 | — | — | US | disclosed |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2018-01-04 | — | — | US | disclosed |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-28 | — | — | US | disclosed |
| US-20170362605-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9840533-B2 | Compositions and methods for altering second messenger signaling | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-07 | — | — | US | disclosed |
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9814760-B2 | Modified polynucleotides for the production of biologics and proteins associated with human disease | MODERNATX, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3233132-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | Modernatx, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9790531-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782462-B2 | Modified polynucleotides for the production of proteins associated with human disease | MODERNATX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170202979-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNATX, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204422-A1 | CIRCULAR POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| WO-2017123568-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2017100461-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | SOLSTICE BIOLOGICS, LTD. (IE) | 2017-06-15 | — | — | WO | disclosed |
| EP-3177732-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | ModernaTX, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9675668-B2 | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 | MODERNA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-3169783-A2 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | Modernatx, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3169335-A2 | CIRCULAR POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3169693-A1 | CHIMERIC POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170130255-A1 | ENZYMES AND POLYMERASES FOR THE SYNTHESIS OF RNA | MODERNATX, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| EP-2061450-B1 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MEDICAL COLLEGE WISCONSIN INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20170097359-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2017-04-06 | — | — | US | disclosed |
| US-9597380-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | INSPIRNA, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9587003-B2 | Modified polynucleotides for the production of oncology-related proteins and peptides | MODERNATX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9572897-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9572896-B2 | In vivo production of proteins | MODERNATX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX INC (US) | 2017-02-02 | — | — | US | disclosed |
| US-20160375134-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-12-29 | — | — | US | disclosed |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-9512456-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511072-B2 | Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9504734-B2 | Modified polynucleotides for the production of nuclear proteins | MODERNATX, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160331828-A1 | NUCLEIC ACID VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160317647-A1 | NUCLEIC ACID VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160289674-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | MODERNATX, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160279272-A1 | RESIDUALIZING LINKERS AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2016-09-29 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160237108-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-18 | — | — | US | disclosed |
| EP-3053585-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160205924-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | MODERNATX, INC. | 2016-07-21 | — | — | US | disclosed |
| US-9394256-B2 | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof | X-CHEM, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394296-B2 | Tryptoline derivatives having kinase inhibitory activity and uses thereof | X-CHEM, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160199513-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | ARES CAPITAL CORPORATION, AS AGENT | 2016-07-14 | — | — | US | disclosed |
| US-20160199506-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2016-07-14 | — | — | US | disclosed |
| EP-3041934-A1 | CHIMERIC POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-3041938-A1 | CIRCULAR POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160194368-A1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194625-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193299-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2016-07-07 | — | — | US | disclosed |
| WO-2016100812-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160158385-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-06-09 | — | — | US | disclosed |
| US-20160151516-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-06-02 | — | — | US | disclosed |
| US-20160152678-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2016-06-02 | — | — | US | disclosed |
| EP-2918275-B1 | Alternative nucleic acid molecules and uses thereof | MODERNA THERAPEUTICS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160114011-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-04-28 | — | — | US | disclosed |
| US-9301993-B2 | Modified polynucleotides encoding apoptosis inducing factor 1 | MODERNA THERAPEUTICS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303079-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNA THERAPEUTICS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9295689-B2 | Formulation and delivery of PLGA microspheres | MODERNA THERAPEUTICS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160075733-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | ARES CAPITAL CORPORATION, AS AGENT | 2016-03-17 | — | — | US | disclosed |
| US-9283287-B2 | Modified polynucleotides for the production of nuclear proteins | MODERNA THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20160068560-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2991655-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | Memorial Sloan Kettering Cancer Center (US) | 2016-03-09 | — | — | EP | disclosed |
| US-9271996-B2 | Formulation and delivery of PLGA microspheres | MODERNA THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160038612-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | ARES CAPITAL CORPORATION, AS AGENT | 2016-02-11 | — | — | US | disclosed |
| WO-2016022914-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | MODERNA THERAPEUTICS, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-9255129-B2 | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 | MODERNA THERAPEUTICS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9254311-B2 | Modified polynucleotides for the production of proteins | MODERNA THERAPEUTICS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20160024181-A1 | LONG-LIVED POLYNUCLEOTIDE MOLECULES | MODERNATX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160022840-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2016011226-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011306-A2 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011222-A2 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| EP-2971010-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | Moderna Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968391-A1 | LONG-LIVED POLYNUCLEOTIDE MOLECULES | Moderna Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2964234-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | Moderna Therapeutics, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9233141-B2 | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders | MODERNA THERAPEUTICS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150376648-A1 | IN VIVO PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376665-A1 | PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION | CONCERT PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9221891-B2 | In vivo production of proteins | MODERNA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220755-B2 | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders | MODERNA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220792-B2 | Modified polynucleotides encoding aquaporin-5 | MODERNA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150368665-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2015-12-24 | — | — | US | disclosed |
| US-9216205-B2 | Modified polynucleotides encoding granulysin | MODERNA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9192651-B2 | Modified polynucleotides for the production of secreted proteins | MODERNA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9186372-B2 | Split dose administration | MODERNA THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150315541-A1 | MODIFIED POLYNUCLEOTIDES FOR ALTERING CELL PHENOTYPE | MODERNATX, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| EP-2931914-A1 | MODIFIED POLYNUCLEOTIDES FOR ALTERING CELL PHENOTYPE | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9149506-B2 | Modified polynucleotides encoding septin-4 | MODERNA THERAPEUTICS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2922554-A1 | TERMINALLY MODIFIED RNA | Moderna Therapeutics, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-2918275-A1 | Alternative nucleic acid molecules and uses thereof | Roy, Atanu (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150246139-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2015-09-03 | — | — | US | disclosed |
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| US-9114113-B2 | Modified polynucleotides encoding citeD4 | MODERNA THERAPEUTICS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9107886-B2 | Modified polynucleotides encoding basic helix-loop-helix family member E41 | MODERNA THERAPEUTICS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9095552-B2 | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 | MODERNA THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150211039-A1 | ENZYMES AND POLYMERASES FOR THE SYNTHESIS OF RNA | ARES CAPITAL CORPORATION, AS AGENT | 2015-07-30 | — | — | US | disclosed |
| US-9089604-B2 | Modified polynucleotides for treating galactosylceramidase protein deficiency | MODERNA THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9085788-B2 | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation | CONCERT PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9074233-B2 | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation | CONCERT PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2885313-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | The Regents of The University of California (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2885419-A2 | ENZYMES AND POLYMERASES FOR THE SYNTHESIS OF RNA | Moderna Therapeutics, Inc. (US) | 2015-06-24 | — | — | EP | disclosed |
| US-9061059-B2 | Modified polynucleotides for treating protein deficiency | MODERNA THERAPEUTICS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150166616-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2015-06-18 | — | — | US | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-9050297-B2 | Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator | MODERNA THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150111248-A1 | IN VIVO PRODUCTION OF PROTEINS | MODERNA THERAPEUTICS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-8999380-B2 | Modified polynucleotides for the production of biologics and proteins associated with human disease | MODERNA THERAPEUTICS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20150086614-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | MODERNA THERAPEUTICS, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2849799-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | Moderna Therapeutics, Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| WO-2015034925-A1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015034928-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150064235-A1 | MODIFIED POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2015-03-05 | — | — | US | disclosed |
| US-20150064236-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2015-03-05 | — | — | US | disclosed |
| US-20150051268-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | MODERNATX, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20150050354-A1 | MODIFIED POLYNUCLEOTIDES FOR THE TREATMENT OF OTIC DISEASES AND CONDITIONS | MODERNATX, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20150044277-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CASPASE 3 | MODERNA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| EP-2833922-A2 | IN VIVO PRODUCTION OF PROTEINS | Moderna Therapeutics, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| EP-2833921-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | Moderna Therapeutics, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| EP-2834260-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | Moderna Therapeutics, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| EP-2834358-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | Moderna Therapeutics, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| EP-2834259-A1 | MODIFIED POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| EP-2833923-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS | Moderna Therapeutics, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| EP-2833892-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | Moderna Therapeutics, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-20150030576-A1 | METHODS AND COMPOSITIONS FOR TARGETING AGENTS INTO AND ACROSS THE BLOOD-BRAIN BARRIER | MODERNATX, INC. | 2015-01-29 | — | — | US | disclosed |
| US-20150005345-A1 | BENZHYDROL-PYRAZOLE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2015-01-01 | — | — | US | disclosed |
| US-20150005310-A1 | TRYPTOLINE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-Rx, Inc (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | MODERNATX, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140343129-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2014-11-20 | — | — | US | disclosed |
| EP-2802324-A1 | BENZHYDROL-PYRAZOLE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-RX, Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2802328-A1 | TRYPTOLINE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-RX, Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140329811-A1 | Methods of Modulating Cell Proliferation and Cyst Formation in Polycystic Kidney and Liver Diseases | MCW RESEARCH FOUNDATION, INC. | 2014-11-06 | — | — | US | disclosed |
| WO-2014179335-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2014-11-06 | — | — | WO | disclosed |
| EP-2791159-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | Moderna Therapeutics, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2791160-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | Moderna Therapeutics, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2791364-A1 | METHODS OF RESPONDING TO A BIOTHREAT | Moderna Therapeutics, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| WO-2014164253-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014159813-A1 | LONG-LIVED POLYNUCLEOTIDE MOLECULES | MODERNA THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-8846764-B2 | Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014152211-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275229-A1 | MODIFIED POLYNUCLEOTIDES ENCODING UDP GLUCURONOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1 | MODERNA THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140255467-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 | MODERNA THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140255468-A1 | MODIFIED POLYNUCLEOTIDES ENCODING PROGRAMMED CELL DEATH 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140249208-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140221465-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING GALACTOSYLCERAMIDASE PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140206852-A1 | SIGNAL-SENSOR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206755-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING ARYLSULFATASE A PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140193482-A1 | MODIFIED POLYNUCLEOTIDES ENCODING V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG | MODERNA THERAPEUTICS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194494-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140186432-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CITED4 | MODERNA THERAPEUTICS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014093574-A1 | MODIFIED POLYNUCLEOTIDES FOR ALTERING CELL PHENOTYPE | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140171485-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CD28 MOLECULE | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8754062-B2 | DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides | MODERNA THERAPEUTICS, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140161873-A1 | MODIFIED POLYNUCLEOTIDES ENCODING ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR | MODERNA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140155474-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING CYSTIC FIBROSIS | MODERNA THERAPEUTICS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155473-A1 | MODIFIED GLUCOSIDASE, BETA, ACID POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY | Moderna Threrapeutics, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155475-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING LIPASE A, LYSOSOMAL ACID, CHOLESTEROL ESTERASE PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155472-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING ARGININOSUCCINATE SYNTHASE 1 PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2014081507-A1 | TERMINALLY MODIFIED RNA | MODERNA THERAPEUTICS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140147432-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH BLOOD AND LYMPHATIC DISORDERS | MODERNA THERAPEUTICS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140147454-A1 | TERMINALLY MODIFIED RNA | MODERNA THERAPEUTICS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148502-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140141068-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SIAH E3 UBIQUITIN PROTEIN LIGASE 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140113960-A1 | MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN | MODERNA THERAPEUTICS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113959-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CASPASE 6 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140105964-A1 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140105965-A1 | MODIFIED POLYNUCLEOTIDES ENCODING COPPER METABOLISM (MURR1) DOMAIN CONTAINING 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140105966-A1 | MODIFIED POLYNUCLEOTIDES ENCODING HEPATITIS A VIRUS CELLULAR RECEPTOR 2 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8680069-B2 | Modified polynucleotides for the production of G-CSF | MODERNA THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8664194-B2 | Method for producing a protein of interest in a primate | MODERNA THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2014031575-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014028429-A2 | ENZYMES AND POLYMERASES FOR THE SYNTHESIS OF RNA | MODERNA THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20140046060-A1 | METHOD OF UTILIZING RECYCLED DEUTERIUM OXIDE IN THE SYNTHESIS OF DEUTERATED COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140017739-A1 | PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION | CONCERT PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140010861-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | modeRNA Therapeutics (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130280768-A1 | PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION | CONCERT PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130266640-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2013-10-10 | — | — | US | disclosed |
| WO-2013151672-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013151663-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013151664-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013151667-A1 | MODIFIED POLYNUCLEOTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013151668-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013151670-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013151736-A2 | IN VIVO PRODUCTION OF PROTEINS | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013151665-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130259924-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | modeRNA Therapeutics (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130259923-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | modeRNA Therapeutics (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130253043-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF G-CSF | modeRNA Therapeutics (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252281-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130244279-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245106-A1 | METHOD OF PRODUCING A PROTEIN OF INTEREST | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244278-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245105-A1 | DLIN-KC2-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245104-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST IN A PRIMATE | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130237593-A1 | MULTI-SITE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2013130161-A1 | METHODS OF RESPONDING TO A BIOTHREAT | modeRNA Therapeutics (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013106432-A1 | BENZHYDROL-PYRAZOLE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-RX, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013106414-A1 | TRYPTOLINE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-RX, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2013090648-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090186-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2012031068-A1 | METHOD OF UTILIZING RECYCLED DEUTERIUM OXIDE IN THE SYNTHESIS OF DEUTERATED COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031073-A1 | PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION | CONCERT PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031072-A1 | PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION | CONCERT PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| US-7589094-B2 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-2061450-A2 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MCW Research Foundation, Incorporated (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080167382-A1 | By administering a 20-hydroxyeicosatetraenoic acid (20-HETE) synthesizing enzyme inhibitor or a 20-HETE antagonist; antiproliferative agents | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008034011-A2 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MCW RESEARCH FOUNDATION, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1291343-B1 | HYDROXYFORMAMIDINE DERIVATIVES AND MEDICINES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-20060194817-A1 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-7078400-B2 | 20-HETE synthase inhibitor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-18 | — | — | US | disclosed |
| CN-1250209-C | 20-Hydroxyeicosatetraenoic acid synthase inhibitors | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-04-12 | — | — | CN | disclosed |
| EP-1226819-B1 | INHIBITOR FOR 20-HETE-YIELDING ENZYME | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6864254-B1 | Inhibitor for 20-hete-yielding enzyme | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-03-08 | — | — | US | disclosed |
| US-20040110830-A1 | 20-HETE synthase inhibitor | TAISHO PHARMACEUTICAL CO., LTD. | 2004-06-10 | — | — | US | disclosed |
| US-6670382-B2 | For inhibiting a synthase of 20-hydroxyeicosatetraenoic acid biosynthesized from arachidonic acid involved in constriction or dilation of microvessels in the kidneys and the cerebral blood vessels, or participates in cell proliferation | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-30 | — | — | US | disclosed |
| US-20030186979-A1 | Hydroxyformamidine derivatives and medicines containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-0733633-B1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-1291343-A1 | HYDROXYFORMAMIDINE DERIVATIVES AND MEDICINES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-03-12 | — | — | EP | disclosed |
| CN-1382045-A | Inhibitor for 20-hydroxy-eicosatetraenoic acid enzyme | TAISHO PHARMACEUTICAL CO LTD (JP) | 2002-11-27 | — | — | CN | disclosed |
| EP-1226819-A1 | INHIBITOR FOR 20-HETE-YIELDING ENZYME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001034573-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034578-A1 | COMPOUNDS WITH ANTI-HELICOBACTER PYLORI ACTIVITY | ASTRAZENECA AB (SE) | 2001-05-17 | — | — | WO | disclosed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | disclosed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | disclosed |
| US-5753664-A | ANTITUMOR AGENTS, PYRIMIDONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5741794-A | PLATELET ACTIVATING FACTOR | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-04-21 | — | — | US | disclosed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | disclosed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | disclosed |
| EP-0620813-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993014069-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| EP-0320939-B1 | SILVER HALIDE COLOR PHOTOGRAPHIC MATERIAL | FUJI PHOTO FILM CO., LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0320939-A2 | Silver halide color photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1989-06-21 | — | — | EP | disclosed |
| EP-0177087-A2 | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-04-09 | — | — | EP | disclosed |
| US-4548939-A | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones | JANSSEN PHARMACEUTICA N. V. (BE) | 1985-10-22 | — | — | US | disclosed |
| US-4400381-A | ANTIHISTAMINES FOR RESPIRATORY DISORDERS | LAROCHE-NAVARRON, S.A. (FR) | 1983-08-23 | — | — | US | disclosed |
| EP-0072307-A1 | Piperazine derivatives of theophylline | LABORATOIRES SYNTEX (FR) | 1983-02-16 | — | — | EP | disclosed |
| EP-0001650-B1 | ACYLACETANILIDE COMPOUNDS AND THEIR USE AS YELLOW FORMING COLOUR COUPLERS FOR SILVER HALIDE PHOTOGRAPHY | AGFA-GEVAERT N.V. (BE) | 1982-07-28 | — | — | EP | disclosed |
| US-4241168-A | TWO-EQUIVALENT MAGENTA COUPLER | FUJI PHOTO FILM CO., LTD. (JP) | 1980-12-23 | — | — | US | disclosed |
| US-4201584-A | Silver halide elements containing yellow forming color couplers for silver halide photography | AGFA-GEVAERT N.V. (BE) | 1980-05-06 | — | — | US | disclosed |
| EP-0001650-A1 | Acylacetanilide compounds and their use as yellow forming colour couplers for silver halide photography | AGFA-GEVAERT N.V. (BE) | 1979-05-02 | — | — | EP | disclosed |
| EP-0001650-A1 | Acylacetanilide compounds and their use as yellow forming colour couplers for silver halide photography | AGFA-GEVAERT N.V. (BE) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | SEPTIN7, SEPTIN9, SEPTIN8 | GDA 1967/4885ACHE 4864/4885XDH 4009/4885 |
| US-10155029-B2 | Terminally modified RNA | RNGTT, NSUN3, RNMT | GDA 1085/4885ACHE 4863/4885XDH 4810/4885 |
| US-10385088-B2 | Polynucleotide molecules and uses thereof | NSUN3, POLRMT, TRDMT1 | GDA 345/4885ACHE 4266/4885XDH 3238/4885 |
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | NSUN3, TRDMT1, NSUN2 | GDA 485/4885ACHE 3658/4885XDH 4794/4885 |
| US-20220088231-A1 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | MRE11, DCLRE1A, RAD50 | GDA 729/4885ACHE 4670/4885XDH 4240/4885 |
| US-20130237593-A1 | MULTI-SITE ADMINISTRATION | PHAX, IGF2BP1, NSUN2 | GDA 884/4885ACHE 4749/4885XDH 4773/4885 |
| US-20190343941-A1 | CARBOHYDRATE STRUCTURES AND USES THEREOF | UGCG, CD4, CD2 | GDA 843/4885ACHE 971/4885XDH 3689/4885 |
| US-20140113959-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CASPASE 6 | CASP6, MSH6, PARP6 | GDA 514/4885ACHE 4734/4885XDH 1777/4885 |
| US-20190055277-A1 | Immune Modulatory Compositions | STING1, IFNAR1, IRF3 | GDA 1363/4885ACHE 1918/4885XDH 997/4885 |
| US-20190315824-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MSH2, POLRMT, SARNP | GDA 1304/4885ACHE 4831/4885XDH 2788/4885 |
| US-10093741-B1 | IGF-1R monoclonal antibodies and uses thereof | IGF1R, IGFBP1, IGFBP2 | GDA 3490/4885ACHE 4778/4885XDH 4581/4885 |
| US-20230227826-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | HNRNPR, HNRNPK, ATXN2 | GDA 3600/4885ACHE 4054/4885XDH 3341/4885 |
| US-20150246139-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | GDA 1128/4885ACHE 4857/4885XDH 2486/4885 |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | GDA 36/4885ACHE 4868/4885XDH 2049/4885 |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | GDA 231/4885ACHE 4179/4885XDH 2422/4885 |
| US-20220275362-A1 | METHODS FOR TAGGING AND ENCODING OF PRE-EXISTING COMPOUND LIBRARIES | NUDT21, NSUN2, NSUN3 | GDA 505/4885ACHE 2144/4885XDH 1251/4885 |
| US-20210060190-A1 | RESIDUALIZING LINKERS AND USES THEREOF | CD44, CD47, MTCL3 | GDA 1199/4885ACHE 707/4885XDH 2379/4885 |
| US-20160038612-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, ADAR | GDA 173/4885ACHE 4663/4885XDH 4317/4885 |
| US-20230270895-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | CD274, PDCD1, PDCD1LG2 | GDA 1578/4885ACHE 3659/4885XDH 4096/4885 |
| US-20230151022-A1 | PRINS REACTION AND COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ANALOGS THEREOF | LSS, DHPS, COASY | GDA 1973/4885ACHE 3780/4885XDH 3268/4885 |
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | GDA 43/4885ACHE 4252/4885XDH 1174/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | GDA 36/4885ACHE 4868/4885XDH 2049/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | GDA 43/4885ACHE 4252/4885XDH 1174/4885 |
| US-20190015501-A1 | NUCLEIC ACID VACCINES | NSUN3, NSUN2, RNGTT | GDA 337/4885ACHE 4462/4885XDH 4484/4885 |
| US-20210290789-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | CD274, PDCD1, PDCD1LG2 | GDA 1578/4885ACHE 3659/4885XDH 4096/4885 |
| US-20140105964-A1 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 | AQP1, AQP3, AQP4 | GDA 1118/4885ACHE 4827/4885XDH 2369/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | GDA 43/4885ACHE 4252/4885XDH 1174/4885 |
| US-20180000910-A1 | TERMINALLY MODIFIED RNA | RNGTT, NSUN3, RNMT | GDA 1085/4885ACHE 4863/4885XDH 4810/4885 |
| US-20220144849-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | CEP170, PIN1, FKBP3 | GDA 3675/4885ACHE 4035/4885XDH 4653/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | GDA 36/4885ACHE 4868/4885XDH 2049/4885 |
| US-20180127454-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | CGAS, PDE7A, PRKG1 | GDA 109/4885ACHE 2401/4885XDH 1090/4885 |
| US-20220143202-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | PIN1, FKBP4, FKBP2 | GDA 1921/4885ACHE 4517/4885XDH 4422/4885 |
| US-20150051268-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | GDA 776/4885ACHE 4496/4885XDH 3885/4885 |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | GDA 1974/4885ACHE 4827/4885XDH 4748/4885 |
| US-20160199506-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | PIN1, FKBP4, FKBP2 | GDA 1921/4885ACHE 4517/4885XDH 4422/4885 |
| US-10407683-B2 | Circular polynucleotides | POLN, POLRMT, POLI | GDA 616/4885ACHE 4780/4885XDH 4552/4885 |
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | BACE1, APP, BACE2 | GDA 1996/4885ACHE 58/4885XDH 1942/4885 |
| US-20180360995-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES | MSH2, POLRMT, MSH6 | GDA 771/4885ACHE 4455/4885XDH 3175/4885 |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | GDA 1128/4885ACHE 4857/4885XDH 2486/4885 |
| US-20140206852-A1 | SIGNAL-SENSOR POLYNUCLEOTIDES | POLRMT, MSH2, MAVS | GDA 674/4885ACHE 4846/4885XDH 2541/4885 |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | IGF2BP1, PHAX, IGF2BP2 | GDA 950/4885ACHE 4675/4885XDH 4369/4885 |
| US-11981703-B2 | Polynucleotide constructs | PHAX, CPSF6, RNGTT | GDA 2604/4885ACHE 2357/4885XDH 3991/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | GDA 776/4885ACHE 4496/4885XDH 3885/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | GDA 83/4885ACHE 4861/4885XDH 1523/4885 |
| US-20140113960-A1 | MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN | GMNN, POLN, RNMT | GDA 289/4885ACHE 4870/4885XDH 3120/4885 |
| US-20180291335-A1 | MODIFIED POLYNUCLEOTIDES FOR ALTERING CELL PHENOTYPE | MSH2, POLN, PMS2 | GDA 1158/4885ACHE 4839/4885XDH 3411/4885 |
| US-20160331828-A1 | NUCLEIC ACID VACCINES | NSUN3, NSUN2, RNGTT | GDA 337/4885ACHE 4462/4885XDH 4484/4885 |
| US-20180256750-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | POLR2E, POLN, PHAX | GDA 1735/4885ACHE 4808/4885XDH 4879/4885 |
| US-11014956-B2 | Compositions and methods for altering second messenger signaling | NT5C2, PLA2G4B, PLA2G4C | GDA 327/4885ACHE 2115/4885XDH 1083/4885 |
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | UPF1, HNRNPUL1, HNRNPUL2 | GDA 1296/4885ACHE 4419/4885XDH 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.